The maximum tolerated dose of walking for people with severe osteoarthritis of the knee: a phase I trial Wallis, J.A., Webster, K.E., Levinger, P., Singh, P.J., Fong, C. and Taylor, N.F. 2015, The maximum tolerated dose of walking for people with severe osteoarthritis of the knee: a phase I trial, Osteoarthritis and cartilage, vol. 23, no. 8, pp. 1285-1293, doi: 10.1016/j.joca.2015.04.001. Attached Files Name Description MIMEType Size Downloads Title The maximum tolerated dose of walking for people with severe osteoarthritis of the knee: a phase I trial Author(s) Wallis, J.A. Webster, K.E. Levinger, P. Singh, P.J. Fong, C. Taylor, N.F. Journal name Osteoarthritis and cartilage Volume number 23 Issue number 8 Start page 1285 End page 1293 Total pages 9 Publisher Elsevier Place of publication Amsterdam, The Netherlands Publication date 2015-08 ISSN 1522-9653 Keyword(s) Knee Maximum tolerated dose of walking Osteoarthritis Physical activity Aged Aged, 80 and over Exercise Tolerance Female Humans Male Middle Aged Osteoarthritis, Knee Pain Measurement Severity of Illness Index Time Factors Walking Summary OBJECTIVE: To determine how much physical activity, in the form of walking, can be safely and feasibly tolerated for people with severe knee osteoarthritis (OA). DESIGN: Phase I dose response trial with escalating walking doses of 10, 20, 35, 50, 70, and 95 min over 1 week, were prescribed non-randomly to people with severe knee OA. The primary stopping rule was a substantial increase in knee pain. The primary outcomes were an estimation of the maximum tolerated dose of walking; and the proportion of people who did not complete the dose for feasibility reasons. The secondary outcomes were pain, stiffness and activity limitation Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). RESULTS: Twenty-four participants (13 women) aged 53-83 years, and average body mass index (BMI) of 34 kg/m(2) (SD 9) were recruited. Three participants were assigned to each dose between 10 and 70 min, and nine participants assigned to the 95-min dose. The trial was stopped at 95 min due to the maximum number of adverse events occurring at this dose. Therefore, the maximum tolerated dose was 70 min. No participant stopped due to reasons related to feasibility. There was a moderate association between dose and increased activity (linear R(2) = 0.31, cubic R(2) = 0.69) and reduced stiffness (linear R(2) = 0.20, cubic R(2) = 0.52), with increased benefits at moderate to higher doses. CONCLUSIONS: There is preliminary evidence that 70 min per week of moderate intensity supervised walking was safe and feasible for people with severe OA of the knee; for higher doses there was a risk of exacerbating knee pain levels. Language eng DOI 10.1016/j.joca.2015.04.001 Indigenous content off Field of Research 110399 Clinical Sciences not elsewhere classified 1103 Clinical Sciences Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences HERDC Research category C1.1 Refereed article in a scholarly journal ERA Research output type C Journal article Copyright notice ©2015, Elsevier Persistent URL http://hdl.handle.net/10536/DRO/DU:30081337 Document type: Journal Article Collections: Faculty of Health School of Medicine Related Links Link Description Connect to published version (restricted access) Go to link with your DU access privileges   Connect to Elements publication management system Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Thu, 11 Feb 2016, 14:27:11 EST Tue, 19 Jul 2016, 12:38:15 EST Wed, 20 Jul 2016, 05:01:00 EST Wed, 20 Jul 2016, 06:09:51 EST Wed, 20 Jul 2016, 08:45:00 EST Wed, 20 Jul 2016, 08:45:52 EST Wed, 20 Jul 2016, 08:46:48 EST Wed, 12 Oct 2016, 14:49:53 EST Wed, 01 Mar 2017, 07:46:19 EST Sun, 10 Nov 2019, 20:42:18 EST Sat, 27 Feb 2021, 01:30:30 EST Thu, 13 May 2021, 12:45:22 EST Tue, 06 Jul 2021, 02:35:28 EST Fri, 17 Jun 2022, 23:38:45 EST Filtered Full Citation counts:   Cited 16 times in TR Web of Science Cited 18 times in Scopus Search Google Scholar Access Statistics: 171 Abstract Views, 0 File Downloads  -  Detailed Statistics Created: Tue, 19 Jul 2016, 12:38:15 EST